Revvity, Inc. (RVTY)

Over the past six months, Revvity's stock price has fluctuated, with a 52-week range between $81.36 and $123.34. Key events include the Q4 and Full Year 2025 Earnings Report, which showed better-than-expected earnings but a subsequent stock decline, product launches at SLAS2026, a dividend declaration, a collaboration with Lilly, and the Q3 2025 Earnings Call, which reported a decrease in revenue due to lower COVID-related revenues and softer reagent demand.

While specific detailed seasonality data is not extensively provided, some insights can be inferred from recent earnings reports. The Q3 2025 earnings call mentioned softer reagent and consumable demand, particularly in September, and a downturn in demand from pharma and biotech customers which impacted the Life Sciences business. This suggests that demand for certain products and services can be influenced by factors such as research funding cycles, pharmaceutical and biotech spending, and potentially academic calendars, which may introduce some level of seasonality or quarterly fluctuations in demand. The company also anticipates continued challenges in the China diagnostics market due to DRG-related volume pressures.

Revvity, Inc. is a global life sciences and diagnostics company that emerged in 2023 from the rebranding of PerkinElmer, focusing on health science solutions from discovery to cure. The company operates in two segments: Life Sciences, offering reagents, instruments, and services for biopharma and academic research, and Diagnostics, developing tools and applications for reproductive health, immunodiagnostics, and applied genomics markets.

Revvity's products and services are sold worldwide in over 160 countries, with major markets including the United States, Europe, and China. The United States accounts for 39.8% of net sales, China for 16.3%, and the United Kingdom for 4.1%, with other regions making up the remaining 39.8%. The company's headquarters are in Waltham, Massachusetts, U.S.

Revvity's brand reputation is supported by its continued innovation and financial performance. Positive factors include strong Q4 2025 earnings, new product launches, and strategic collaborations. There have been no publicly reported events in the past year that explicitly detail a negative impact on Revvity's brand reputation.

Revvity's ownership is predominantly held by institutional investors, who collectively manage approximately 97.4% of shares. Major institutional owners include T. Rowe Price Investment Management, Inc., Vanguard Group Inc, BlackRock, Inc., EdgePoint Investment Group Inc., Janus Henderson Group Plc, and State Street Corp. Alexis P. Michas is the largest individual shareholder with 0.60% ownership.